Cancer Statistics, 2021
2021/01/01 by Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs +1 · 70 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Genomics and Diagnostics #Colorectal Cancer Screening and Detection #Global Cancer Incidence and Screening
paper · pdf · doi:10.3322/caac.21654
openalex publication_date 2021/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.
Citations
Cited by
- Lung cancer statistics, 2023
- Cancer treatment and survivorship statistics, 2022
- Brain and other central nervous system tumor statistics, 2021
- Cancer statistics for <scp>A</scp> merican <scp>I</scp> ndian and <scp>A</scp> laska <scp>N</scp> ative individuals, 2022: Including increasing disparities in early onset colorectal cancer
- <i>Fusobacterium nucleatum</i> impairs <scp>DNA</scp> mismatch repair and stability in patients with squamous cell carcinoma of the head and neck
- The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Adenomatous Polyposis Syndromes
- MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer
- Missed Opportunities for Lung Cancer Screening Among Patients With Behavioral Health Disorders With Elevated Cigarette Smoking Rates
- Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche
- N6-Methyladenosine–Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells’ Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways
- Nuclear receptors: from molecular mechanisms to therapeutics
- Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States
- Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort study
- Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response
- Targeting DNA damage repair pathways in pancreas cancer
- Effects of a Web-Based Pediatric Oncology Legacy Intervention on the Coping of Children With Cancer
- The Germline and Somatic Origins of Prostate Cancer Heterogeneity
- Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
- Recent advances in enhancing reactive oxygen species based chemodynamic therapy
- Small cell lung cancer: Subtypes and therapeutic implications
- Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis
- Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial
- Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy
- PIK3CB promotes oesophageal cancer proliferation through the PI3K/AKT/mTOR signalling axis
- Diagnosis and therapeutic strategies of inorganic nanomaterials in lymphatic system diseases
- Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer
- Parallel Mediating Roles of Illness Acceptance Attitudes Between Physical Symptoms and Quality of Life in Patients with Gastrointestinal Cancers
- Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970–2022
- Socioeconomics and attributable etiology of primary liver cancer, 1990-2019
- The clinical impact of androgens in endometrial cancer: cancer promoter or suppressor?
- Fluctuating methylation clocks for cell lineage tracing at high temporal resolution in human tissues
- NXPH4 can be used as a biomarker for pan-cancer and promotes colon cancer progression
- Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review
- Prostate Capsule Segmentation from Micro-Ultrasound Images using Adaptive Focal Loss
- A transformer‐based deep neural network for detection and classification of lung cancer via <scp>PET</scp>/<scp>CT</scp> images
- Multi-Scale Deep Learning for Colon Histopathology: A Hybrid Graph-Transformer Approach
- High-Precision Mixed Feature Fusion Network Using Hypergraph Computation for Cervical Abnormal Cell Detection
- Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer
- Post‐Traumatic Growth in Adult Cancer Survivors: A Scoping Review of Psychological Factors, Predictors, and Interventions
- The age-dependent association of risk factors with pancreatic cancer
- A stemness-based signature with inspiring indications in discriminating the prognosis, immune response, and somatic mutation of endometrial cancer patients revealed by machine learning
- PARP inhibitor BMN673 triggers PARylation-mediated ATF4-GDF15 pathway to drive autophagy and ferroptosis in ataxia telangiectasia mutated gene-deficient colorectal cancer cells
- Conjugated oligo (phenylene vinylene) covalently linked porphyrin for sonodynamic therapy
- Antitumor Effect of Apcin on Endometrial Carcinoma via p21-Mediated Cell Cycle Arrest and Apoptosis
- Flip Learning: Erase to Segment
- KRAS mutation in pancreatic cancer. [europepmc]
- Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. [europepmc]
- Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. [europepmc]
- Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force. [europepmc]
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation. [europepmc]
- The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. [europepmc]
- Pancreatic cancer: A review of epidemiology, trend, and risk factors. [europepmc]
- Pancreatic Cancer: A Review. [europepmc]
- Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. [europepmc]
- Mesenchymal stem/stromal cells in cancer therapy. [europepmc]
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. [europepmc]
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. [europepmc]
- Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. [europepmc]
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. [europepmc]
- Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). [europepmc]
- Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? [europepmc]
- Is early-onset cancer an emerging global epidemic? Current evidence and future implications. [europepmc]
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline. [europepmc]
- Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. [europepmc]
- Single-cell spatial landscapes of the lung tumour immune microenvironment. [europepmc]
- Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). [europepmc]
- Gastric cancer treatment: recent progress and future perspectives. [europepmc]
- Lung microbiome: new insights into the pathogenesis of respiratory diseases. [europepmc]
- Alternative splicing and related RNA binding proteins in human health and disease. [europepmc]
- Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. [europepmc]
Related